A Non-interventional, Multi-centric, Observational, Prospective Study to Collect the Criteria on Which Renewal of GnRH Analogue Treatment With Triptorelin (Diphereline 3.75mg or Diphereline pr 11.25mg) is Made in Patients Recently Diagnosed With Prostate Cancer Requiring Androgen Deprivation Therapy
Phase of Trial: Phase IV
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Triptorelin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms CHRONOS3
- Sponsors Ipsen
- 30 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 30 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 28 Jul 2016 Planned End Date changed from 1 Jul 2016 to 1 Dec 2016.